Ribi ImmunoChem liposome contract
Executive Summary
Six-month, $50,000 Small Business Innovative Research grant from the National Institute of Allergy and Infectious Diseases has been awarded to firm to conduct Phase I studies of its proprietary adjuvants in liposome vaccine delivery systems. The project will include formulating the company's adjuvant products with genetically engineered and synthetic subunit antigens into liposomes. Ribi said it will apply for a $500,000 Phase II research grant if the studies are successful.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.